Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis

Autor: van der Tjipke Werf, J A Dijkstra, Jos G. W. Kosterink, Onno W. Akkerman, R. van Altena, Johannes H. Proost, de Wiel Lange, Jan-Willem C. Alffenaar

Publikováno v: International journal of antimicrobial agents, 46(3), 332-337. Elsevier Bedrijfsinformatie b.v.
International Journal of Antimicrobial Agents, 46(3), 332-7. Elsevier
Dijkstra, J A, van Altena, R, Akkerman, O W, de Lange, W C M, Proost, J H, van der Werf, T S, Kosterink, J G W & Alffenaar, J W C 2015, ' Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis ', International Journal of Antimicrobial Agents, vol. 46, no. 3, pp. 332-7 . https://doi.org/10.1016/j.ijantimicag.2015.06.008

Amikacin and kanamycin are considered important and effective drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB). Unfortunately, the incidence of toxicity is high and is related to elevated drug exposure. In order to achieve a balanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::351435ad6c3fbe3672a87074ad2aa5b7
https://doi.org/10.1016/j.ijantimicag.2015.06.008

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis

Autor: J A Dijkstra, Jan-Willem C. Alffenaar, M E van der Meer, J F Borjas Howard, R. van Altena, D. van Soolingen, T S van der Werf, Jos G. W. Kosterink

Publikováno v: Antimicrobial Agents and Chemotherapy, 61, e01400-16-e01400-16
Antimicrobial Agents and Chemotherapy, 61(3). American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 61(3):UNSP e01400-16. AMER SOC MICROBIOLOGY
van Altena, R, Dijkstra, J A, van der Meer, M E, Borjas Howard, J F, Kosterink, J G W, van Soolingen, D, van der Werf, T S & Alffenaar, J W C 2017, ' Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis ', Antimicrobial Agents and Chemotherapy, vol. 61, no. 3 . https://doi.org/10.1128/AAC.01400-16
Antimicrobial Agents and Chemotherapy, 61, 3, pp. e01400-16-e01400-16

Hearing loss and nephrotoxicity are associated with prolonged treatment duration and higher dosage of amikacin and kanamycin. In our tuberculosis center, we used therapeutic drug monitoring (TDM) targeting preset pharmacokinetic/pharmacodynamic (PK/P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bdac79b0c4f8853428eac4d08e28050
http://hdl.handle.net/2066/170279

Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis

Autor: S. Ahuja, Vija Riekstina, Wing Wai Yew, Giovanni Sotgiu, Jennifer Flood, José María Peña, Melissa Bauer, Carlos Pérez-Guzmán, Payam Tabarsi, Matthew Strand, Domingo Palmero, M. Van der Walt, Tae Sun Shim, Yuji Shiraishi, Thelma E. Tupasi, Helen Cox, P. O'Riordan, Lia D'Ambrosio, W C M de Lange, R. Banerjee, Jérôme Robert, Chi Chiu Leung, G. B. Migliori, M. I. D. Quelapio, M. Avendano, Maria Graciela Hollm-Delgado, Joey Lancaster, Rosella Centis, Vaira Leimane, Mario H. Vargas, Michael D. Iseman, Reuben Granich, Leah G. Jarlsberg, Sarah Royce, Piret Viiklepp, Won-Jung Koh, H S Schaaf, Jae-Joon Yim, Donald A. Enarson, R. van Altena, D. Ashkin, Dennis Falzon, Salmaan Keshavjee, Masahiro Narita, Kwonjune J. Seung, Marcos Burgos, Janice Westenhouse, Lourdes García-García, Geoffrey Pasvol, Lena Shah, H. R. Kim, Edward D. Chan, Katie L. Flanagan, Mercedes C. Becerra, J. Sifuentes-Osornio, Christoph Lange, Jaime Bayona, Shama D. Ahuja, Timothy H. Holtz, T S van der Werf, Sonya Shin, Andrea Benedetti, Madhukar Pai, Alfredo Ponce-de-León, K. De Riemer, J. Li, Greg J. Fox, Carole D. Mitnick, Neel R. Gandhi, Seung-kyu Park, Chen Yuan Chiang, Dick Menzies, N. H. Dung

Publikováno v: The European respiratory journal. 49(1)

The role of so-called “group 5” second-line drugs as a part of antibiotic therapy for multidrug-resistant tuberculosis (MDR-TB) is widely debated. We performed an individual patient data meta-analysis to evaluate the effectiveness of several grou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3dfc66aab0e79cd1afebb81f53b92ae
https://pubmed.ncbi.nlm.nih.gov/28049180

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

Autor: Rob E. Aarnoutse, Arianna D. Pranger, van der Tjipke Werf, D. van Soolingen, Jan-Willem C. Alffenaar, Jos G. W. Kosterink, Donald R. A. Uges, R. van Altena

Publikováno v: European Respiratory Journal, 38, 4, pp. 888-94
European Respiratory Journal, 38, 888-94
European Respiratory Journal, 38(4), 888-894. EUROPEAN RESPIRATORY SOC JOURNALS LTD

Item does not contain fulltext Moxifloxacin (MFX) is a powerful second-line anti-tuberculosis (TB) agent, but the optimal dose has not yet been established and long-term safety data are scarce. We retrospectively reviewed the medical charts of TB pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8052ffca499b90c94091c2855fc2ca5f
https://doi.org/10.1183/09031936.00176610